Non-Infectious Macular Edema Treatment

Non-Infectious Macular Edema Treatment

Global Non-Infectious Macular Edema Treatment Market to Reach US$25.0 Billion by 2030

The global market for Non-Infectious Macular Edema Treatment estimated at US$17.1 Billion in the year 2023, is expected to reach US$25.0 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2023-2030. Anti-VEGF Drug, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$16.6 Billion by the end of the analysis period. Growth in the Corticosteroids Drug segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 5.2% CAGR

The Non-Infectious Macular Edema Treatment market in the U.S. is estimated at US$4.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 5.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.2% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Non-Infectious Macular Edema Treatment Market - Key Trends & Drivers Summarized

What Is Non-Infectious Macular Edema and Why Is Treatment Essential?
Non-infectious macular edema is a condition characterized by the accumulation of fluid in the macula, the central part of the retina responsible for sharp vision. This condition is commonly associated with diseases such as diabetic retinopathy, uveitis, and retinal vein occlusion (RVO), and leads to blurred or distorted vision if left untreated. Treatment for non-infectious macular edema includes corticosteroids, anti-vascular endothelial growth factor (anti-VEGF) injections, non-steroidal anti-inflammatory drugs (NSAIDs), and laser therapy, all aimed at reducing fluid buildup, inflammation, and preventing vision loss.

The importance of treating non-infectious macular edema lies in its ability to preserve vision and prevent complications such as permanent blindness. Early and effective treatment is crucial for maintaining quality of life, especially for patients with underlying chronic conditions like diabetes. The treatment landscape has advanced significantly with the introduction of anti-VEGF therapies, which specifically target the abnormal blood vessels that contribute to fluid leakage and macular swelling, offering patients better outcomes and fewer side effects than traditional treatments.

How Is the Non-Infectious Macular Edema Treatment Market Evolving?
The non-infectious macular edema treatment market is evolving with the increasing availability of targeted biologic therapies such as anti-VEGF injections, which have become the standard of care for many patients. One key trend is the growing use of these biologics, including ranibizumab and aflibercept, which are designed to inhibit the growth of abnormal blood vessels and reduce fluid leakage in the retina. These therapies are proving to be highly effective in improving vision and reducing the need for more invasive treatments, such as laser therapy or surgery.

Another significant trend is the development of long-acting corticosteroid implants and sustained-release drug delivery systems. These innovations reduce the frequency of treatments, offering patients more convenience and better adherence to their treatment regimens. Additionally, advancements in imaging technologies, such as optical coherence tomography (OCT), are improving the diagnosis and monitoring of macular edema, enabling more precise and individualized treatment approaches. As researchers continue to explore new therapies targeting inflammation and fluid accumulation, the market is expected to expand with more options for patients.

Which Patient Groups Are Driving the Demand for Macular Edema Treatment?
The demand for non-infectious macular edema treatments is largely driven by patients with underlying chronic conditions that increase the risk of macular edema, particularly individuals with diabetic retinopathy. As diabetes becomes more prevalent globally, the incidence of diabetic macular edema is rising, leading to higher demand for effective therapies. Similarly, patients with retinal vein occlusion (RVO), a condition that can cause fluid accumulation in the retina, are significant users of macular edema treatments.

Another key patient group includes individuals with uveitis, an inflammatory disease of the eye that can lead to macular edema. These patients often require corticosteroids or immunosuppressive therapies to manage inflammation and prevent vision loss. The aging population is also a key driver of demand, as older adults are more likely to experience macular edema due to age-related retinal conditions. Early diagnosis and timely treatment are critical for these patients to preserve vision and maintain independence.

What Are the Key Growth Drivers in the Non-Infectious Macular Edema Treatment Market?
The growth in the non-infectious macular edema treatment market is driven by several key factors, starting with the rising prevalence of diabetes and associated retinal complications like diabetic macular edema. As more people are diagnosed with diabetes worldwide, the need for effective treatments for macular edema is increasing. Another critical driver is the widespread adoption of anti-VEGF therapies, which have significantly improved outcomes for patients with macular edema by reducing fluid accumulation and improving vision.

Technological advancements in drug delivery systems, such as sustained-release implants, are also fueling market growth by providing longer-lasting treatments and reducing the burden of frequent injections. Additionally, the aging population is contributing to the demand for macular edema therapies, as age-related eye conditions become more common. The increasing focus on early diagnosis and treatment, supported by advanced imaging techniques like optical coherence tomography (OCT), is further driving market expansion by enabling more precise and effective treatment strategies.

Select Competitors (Total 46 Featured) -

• AbbVie, Inc.
• Alimera Sciences, Inc.
• Allergan PLC
• Amgen, Inc.
• Bausch Health Companies, Inc.
• Bayer AG
• Clearside Biomedical, Inc.
• F. Hoffmann-La Roche AG
• Novartis International AG
• Pfizer, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.